| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Albert R. La Spada | Q67390362 |
| P2093 | author name string | John M Ravits | |
| P2860 | cites work | The Role of Axonal Transport in Neurodegenerative Disease Spread: A Meta-Analysis of Experimental and Clinical Poliomyelitis Compares with Amyotrophic Lateral Sclerosis | Q67702685 |
| Motor neuron disease presenting with respiratory failure | Q71741654 | ||
| Amyotrophic lateral sclerosis with marked neurological asymmetry: clinicopathological study | Q71773124 | ||
| Motor neuron disease: a primary disorder of corticomotoneurons? | Q72577895 | ||
| Human motor units in health and disease | Q73339073 | ||
| Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis | Q73864069 | ||
| Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man | Q75310510 | ||
| Possible pathogenic role of muscle cell dysfunction in motor neuron death in spinal muscular atrophy | Q78059633 | ||
| Twenty-first century brain banking: at the crossroads | Q80890566 | ||
| Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis | Q28131672 | ||
| The Organization of the Frontal Motor Cortex | Q28200645 | ||
| Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up | Q28287954 | ||
| Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons | Q28298056 | ||
| Amyotrophic lateral sclerosis. Its natural history | Q28300675 | ||
| TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis | Q29615597 | ||
| The motor cortex and amyotrophic lateral sclerosis | Q30641917 | ||
| Preclinical and subclinical events in motor neuron disease | Q33627275 | ||
| Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. | Q34578910 | ||
| Amyotrophic lateral sclerosis (ALS): a phylogenetic disease of the corticomotoneuron? | Q35921508 | ||
| Acquired nucleic acid changes may trigger sporadic amyotrophic lateral sclerosis | Q36158213 | ||
| Electrodiagnostic criteria for diagnosis of ALS. | Q37046933 | ||
| Neurovascular signalling defects in neurodegeneration | Q37078102 | ||
| Genetic studies of amyotrophic lateral sclerosis: controversies and perspectives | Q37358932 | ||
| Rethinking ALS: the FUS about TDP-43. | Q37419912 | ||
| Diaphragmatic paralysis in motor neuron disease: Report of two cases and a review of the literature | Q40062900 | ||
| Whole brain-based computerized neuroimaging in ALS and other motor neuron disorders | Q40073448 | ||
| The onset of amyotrophic lateral sclerosis | Q40089644 | ||
| Disease progression in amyotrophic lateral sclerosis: predictors of survival | Q40642209 | ||
| Amyotrophic lateral sclerosis: lower motor neuron disease spreading to upper motor neurons | Q40825607 | ||
| Amyotrophic lateral sclerosis: a critique of a hypothesis | Q41114031 | ||
| Amyotrophic lateral sclerosis: a phylogenetic disease of the corticomotoneuron? Comments on the hypothesis | Q41114036 | ||
| Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis | Q41186937 | ||
| The natural history of motoneuron loss in amyotrophic lateral sclerosis | Q41434654 | ||
| Vulnerability of lower brachial myotomes in motor neurone disease: a clinical and single fibre EMG study | Q41645654 | ||
| Motor neuron disease presenting as acute respiratory failure: a clinical and pathological study | Q42185382 | ||
| Amyotrophic lateral sclerosis in Finland. II: Clinical characteristics | Q43732094 | ||
| Focal loss of anterior horn cells in the cervical cord in motor neuron disease | Q43810159 | ||
| Amyotrophic lateral sclerosis patients living beyond respiratory failure | Q43978773 | ||
| Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. | Q44929155 | ||
| Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem | Q44929159 | ||
| Progression of cortical and spinal dysfunctions over time in amyotrophic lateral sclerosis | Q46849724 | ||
| The natural history of central motor abnormalities in amyotrophic lateral sclerosis | Q48218816 | ||
| Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients | Q48367540 | ||
| Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia | Q48596448 | ||
| The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. | Q51058673 | ||
| Stochastic modelling for quantitative description of heterogeneous biological systems. | Q51856579 | ||
| Amyotrophic lateral sclerosis. A study of its presentation and prognosis. | Q54604898 | ||
| Clinical patterns in progressive muscular atrophy (PMA): a prospective study | Q56929741 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| heterogeneity | Q928498 | ||
| amyotrophic lateral sclerosis | Q206901 | ||
| P304 | page(s) | 805-811 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration | |
| P478 | volume | 73 |
| Q30659482 | 25 years of neuroimaging in amyotrophic lateral sclerosis. |
| Q57592495 | 7-T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosis |
| Q64101735 | A Dynamic Bayesian Network model for the simulation of Amyotrophic Lateral Sclerosis progression |
| Q90600640 | A Phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001) and a single compassionate patient treatment (Protocol GALS-C) |
| Q41708271 | A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study |
| Q38199669 | A seeded propagation of Cu, Zn-superoxide dismutase aggregates in amyotrophic lateral sclerosis. |
| Q37337058 | A(a)LS: Ammonia-induced amyotrophic lateral sclerosis |
| Q40957607 | Accrued somatic mutations (nucleic acid changes) trigger ALS: 2005-2015 update |
| Q55545731 | Advances in motor neurone disease. |
| Q37868435 | Advances in the application of MRI to amyotrophic lateral sclerosis |
| Q36128036 | Age-Related Uptake of Heavy Metals in Human Spinal Interneurons. |
| Q30488423 | Amyotrophic Lateral Sclerosis Survival Score (ALS-SS): A simple scoring system for early prediction of patient survival |
| Q58125262 | Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration |
| Q56531746 | Amyotrophic lateral sclerosis |
| Q36202825 | Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole |
| Q38161789 | Amyotrophic lateral sclerosis--a model of corticofugal axonal spread |
| Q50642868 | Amyotrophic lateral sclerosis-like presentation in a HIV-positive patient. |
| Q84780866 | Amyotrophic lateral sclerosis: Who has the lead, the upper or the lower motor neuron? |
| Q38959347 | Amyotrophic lateral sclerosis: moving towards a new classification system |
| Q34340508 | Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study |
| Q38439914 | Animal models for prion-like diseases. |
| Q41924656 | Apical dendrite degeneration, a novel cellular pathology for Betz cells in ALS |
| Q46031626 | Biological Spectrum of Amyotrophic Lateral Sclerosis Prions. |
| Q50350613 | Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies. |
| Q33567229 | Biology and genetics of prions causing neurodegeneration |
| Q39413097 | Biomarkers in Neurodegenerative Diseases |
| Q37944427 | Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations |
| Q26799233 | Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? |
| Q38196863 | Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients |
| Q44587885 | Can lesions to the motor cortex induce amyotrophic lateral sclerosis? |
| Q38006463 | Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation? |
| Q91651191 | Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics |
| Q38312121 | Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease. |
| Q64228443 | Clinical Measures of Bulbar Dysfunction in ALS |
| Q46017258 | Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS). |
| Q38078984 | Clinical and genetic heterogeneity of amyotrophic lateral sclerosis |
| Q37944429 | Clinical diagnosis and management of amyotrophic lateral sclerosis |
| Q38359194 | Compromised MAPK signaling in human diseases: an update |
| Q36045826 | Controversies and priorities in amyotrophic lateral sclerosis |
| Q34281282 | Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis |
| Q36286068 | Corruption and spread of pathogenic proteins in neurodegenerative diseases |
| Q48241815 | Cortical hyperexcitability and disease spread in amyotrophic lateral sclerosis |
| Q93199197 | Cross-sectional and longitudinal assessment of the upper cervical spinal cord in motor neuron disease |
| Q92186536 | Cu/Zn-superoxide dismutase and wild-type like fALS SOD1 mutants produce cytotoxic quantities of H2O2 via cysteine-dependent redox short-circuit |
| Q37189268 | Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis |
| Q39004348 | Decoding ALS: from genes to mechanism. |
| Q30365956 | Deep learning predictions of survival based on MRI in amyotrophic lateral sclerosis. |
| Q48343790 | Detecting neuronal dysfunction of hand motor cortex in ALS: A MRSI study |
| Q37599978 | Disease mutations in the prion-like domains of hnRNPA1 and hnRNPA2/B1 introduce potent steric zippers that drive excess RNP granule assembly. |
| Q35986198 | Disease spread through contiguity and axonal tracts in primary lateral sclerosis |
| Q53556253 | Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis. |
| Q48114502 | Distinct roles for motor neuron autophagy early and late in the SOD1G93A mouse model of ALS. |
| Q57498880 | Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? |
| Q56929689 | Does the motor cortex influence denervation in ALS? EMG studies of muscles with both contralateral and bilateral corticospinal innervation |
| Q92289432 | Dominant Heterogeneity of Upper and Lower Motor Neuron Degeneration to Motor Manifestation of Involved Region in Amyotrophic Lateral Sclerosis |
| Q44181361 | Dropped head syndrome in amyotrophic lateral sclerosis |
| Q36718274 | Early interneuron dysfunction in ALS: insights from a mutant sod1 zebrafish model |
| Q37280507 | Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy |
| Q38743399 | Exosome secretion is a key pathway for clearance of pathological TDP-43. |
| Q43226624 | Exosome-dependent and independent mechanisms are involved in prion-like transmission of propagated Cu/Zn superoxide dismutase misfolding |
| Q38011636 | Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders |
| Q53076018 | Expression of vesicle-associated membrane-protein-associated protein B cleavage products in peripheral blood leukocytes and cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. |
| Q39041271 | Extra-motor abnormalities in amyotrophic lateral sclerosis: another layer of heterogeneity. |
| Q37241079 | FTD and ALS: a tale of two diseases |
| Q37080289 | FUS-regulated region- and cell-type-specific transcriptome is associated with cell selectivity in ALS/FTLD. |
| Q39000702 | Fixed dynamometry is more sensitive than vital capacity or ALS rating scale |
| Q44215931 | Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study |
| Q26767270 | Focus on Extracellular Vesicles: Physiological Role and Signalling Properties of Extracellular Membrane Vesicles |
| Q26741250 | From animal models to human disease: a genetic approach for personalized medicine in ALS |
| Q38345753 | From nucleation to widespread propagation: A prion-like concept for ALS. |
| Q85020449 | Functional neuroimaging at different disease stages reveals distinct phases of neuroplastic changes in amyotrophic lateral sclerosis |
| Q90265064 | Fungal Neurotoxins and Sporadic Amyotrophic Lateral Sclerosis |
| Q37951515 | Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit. |
| Q51873167 | Genome-wide association study of motor coordination problems in ADHD identifies genes for brain and muscle function. |
| Q37387252 | Glaucoma and amyotrophic lateral sclerosis, two kindred diseases? |
| Q92813735 | Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment |
| Q43739867 | Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality |
| Q83528967 | How does the genetic assassin select its neuronal target? |
| Q52582190 | Human cerebral evolution and the clinical syndrome of amyotrophic lateral sclerosis. |
| Q36739537 | Hyperactive somatostatin interneurons contribute to excitotoxicity in neurodegenerative disorders. |
| Q58556498 | Imaging Biomarkers for the Diagnosis and Prognosis of Neurodegenerative Diseases. The Example of Amyotrophic Lateral Sclerosis |
| Q47624980 | Imaging muscle as a potential biomarker of denervation in motor neuron disease |
| Q37816817 | Implications of the prion-related Q/N domains in TDP-43 and FUS. |
| Q37420398 | In vitro prion-like behaviour of TDP-43 in ALS. |
| Q38653220 | Inhibitory dysfunction in amyotrophic lateral sclerosis: future therapeutic opportunities |
| Q39688083 | Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis |
| Q37992251 | Intercellular (mis)communication in neurodegenerative disease. |
| Q47871638 | Intercellular Prion-Like Conversion and Transmission of Cu/Zn Superoxide Dismutase (SOD1) in Cell Culture |
| Q37628107 | Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms |
| Q30155471 | Intermolecular transmission of superoxide dismutase 1 misfolding in living cells |
| Q24297625 | Intracellular seeded aggregation of mutant Cu,Zn-superoxide dismutase associated with amyotrophic lateral sclerosis |
| Q47280282 | Involvement of spinal sensory pathway in ALS and specificity of cord atrophy to lower motor neuron degeneration |
| Q34022441 | Local transplantation of granulocyte colony-stimulating factor-mobilized human peripheral blood mononuclear cells for unhealing bone fractures |
| Q35239032 | Lockhart Clarke's contribution to the description of amyotrophic lateral sclerosis |
| Q55410798 | Long-Term Air Pollution Exposure and Amyotrophic Lateral Sclerosis in Netherlands: A Population-based Case–control Study. |
| Q47352723 | Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration |
| Q36503560 | Low autophagy capacity implicated in motor system vulnerability to mutant superoxide dismutase |
| Q30490426 | MISSING DATA IMPUTATION IN THE ELECTRONIC HEALTH RECORD USING DEEPLY LEARNED AUTOENCODERS. |
| Q42242501 | Magnetic resonance imaging in amyotrophic lateral sclerosis |
| Q37960903 | Magnetic resonance imaging of pathological processes in rodent models of amyotrophic lateral sclerosis |
| Q38958585 | Management and therapeutic perspectives in amyotrophic lateral sclerosis |
| Q60049281 | Measurement of spinal cord atrophy using phase sensitive inversion recovery (PSIR) imaging in motor neuron disease |
| Q35202637 | Microstructural changes across different clinical milestones of disease in amyotrophic lateral sclerosis |
| Q24619538 | Mimics and chameleons in motor neurone disease |
| Q50178845 | Monitoring Progression of Amyotrophic Lateral Sclerosis Using Ultrasound Morpho-Textural Muscle Biomarkers: A Pilot Study |
| Q30827515 | Monitoring peripheral nerve degeneration in ALS by label-free stimulated Raman scattering imaging |
| Q38258073 | Motoneuron firing in amyotrophic lateral sclerosis (ALS) |
| Q91970420 | Motor Neuron Susceptibility in ALS/FTD |
| Q58278897 | Motor and extramotor neurodegeneration in amyotrophic lateral sclerosis: A 3T high angular resolution diffusion imaging (HARDI) study |
| Q39036805 | Motor neuron disease: biomarker development for an expanding cerebral syndrome |
| Q38597450 | Motor neuron disease: current management and future prospects |
| Q24611300 | Motor neuron involvement in multisystem proteinopathy: implications for ALS |
| Q36890607 | Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis |
| Q48645223 | Navigated transcranial magnetic stimulation in amyotrophic lateral sclerosis. |
| Q43603184 | Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients |
| Q86505386 | Nerve ultrasound in the differentiation of multifocal motor neuropathy (MMN) and amyotrophic lateral sclerosis with predominant lower motor neuron disease (ALS/LMND) |
| Q41574283 | Neural stem cells as a therapeutic approach for amyotrophic lateral sclerosis |
| Q93358596 | Neurochemical correlates of functional decline in amyotrophic lateral sclerosis |
| Q27011744 | Neurodegenerative diseases: expanding the prion concept |
| Q38983572 | Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis |
| Q38384260 | Neuroimaging as a New Diagnostic Modality in Amyotrophic Lateral Sclerosis |
| Q57498892 | Neuroimaging in amyotrophic lateral sclerosis |
| Q83316027 | Neuroimaging in amyotrophic lateral sclerosis |
| Q38121637 | New therapy options for amyotrophic lateral sclerosis |
| Q90382816 | Non-coding RNA in C9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia: A perfect storm of dysfunction |
| Q92778200 | Non-invasive MRI quantification of cerebrospinal fluid dynamics in amyotrophic lateral sclerosis patients |
| Q35592875 | On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia |
| Q37553471 | Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal α-motoneurons in sporadic amyotrophic lateral sclerosis |
| Q26828357 | Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders |
| Q92661380 | Pathophysiology and Diagnosis of ALS: Insights from Advances in Neurophysiological Techniques |
| Q35239043 | Pattern of spread and prognosis in lower limb-onset ALS. |
| Q39227306 | Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis |
| Q48016311 | Patterns of symptom development in patients with motor neuron disease |
| Q38107221 | Peer recommendations on how to improve clinical research, and Conference wrap-up |
| Q35518293 | Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis |
| Q30499509 | Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy |
| Q28748875 | Platelet Serotonin Level Predicts Survival in Amyotrophic Lateral Sclerosis |
| Q36322058 | Prediction of prognosis of ALS: Importance of active denervation findings of the cervical-upper limb area and trunk area |
| Q26824988 | Presymptomatic studies in ALS: rationale, challenges, and approach |
| Q51185924 | Prion Properties of SOD1 in Amyotrophic Lateral Sclerosis and Potential Therapy. |
| Q38176187 | Prion-like activity of Cu/Zn superoxide dismutase: implications for amyotrophic lateral sclerosis. |
| Q26753190 | Prion-like domains as epigenetic regulators, scaffolds for subcellular organization, and drivers of neurodegenerative disease |
| Q38922025 | Prion-like propagation as a pathogenic principle in frontotemporal dementia. |
| Q36426422 | Prion-like propagation of mutant SOD1 misfolding and motor neuron disease spread along neuroanatomical pathways |
| Q50126152 | Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis |
| Q54263747 | Prion-like protein aggregates exploit the RHO GTPase to cofilin-1 signaling pathway to enter cells. |
| Q34447158 | Prognostic factors for the course of functional status of patients with ALS: a systematic review |
| Q91596824 | Prognostic value of time to generalization in 71 Chinese patients with sporadic amyotrophic lateral sclerosis |
| Q41931835 | Progressive hemiparesis (Mills syndrome) with aphasia in amyotrophic lateral sclerosis |
| Q38091029 | Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis. |
| Q47423589 | RNA binding proteins and the pathological cascade in ALS/FTD neurodegeneration |
| Q39564185 | RNA-Binding Proteins in Amyotrophic Lateral Sclerosis and Neurodegeneration. |
| Q37918720 | RNA-binding proteins with prion-like domains in ALS and FTLD-U. |
| Q47142121 | Regional glucose hypometabolic spread within the primary motor cortex is associated with amyotrophic lateral sclerosis disease progression: A fluoro-deoxyglucose positron emission tomography study |
| Q37976113 | Regional spread pattern predicts survival in patients with sporadic amyotrophic lateral sclerosis. |
| Q38994757 | Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis |
| Q36251203 | Relationship between Clinical Parameters and Brain Structure in Sporadic Amyotrophic Lateral Sclerosis Patients According to Onset Type: A Voxel-Based Morphometric Study |
| Q46537325 | Relationship between mutant Cu/Zn superoxide dismutase 1 maturation and inclusion formation in cell models |
| Q30419117 | Relationships between tongue motility, grip force, and survival in SOD1-G93A rats |
| Q37809803 | Research Advances in Amyotrophic Lateral Sclerosis, 2009 to 2010 |
| Q52092218 | Revealing the microstructural brain damage in amyotrophic lateral sclerosis: the relentless pursuit to approach an imaging biomarker. |
| Q36234963 | SOD1 protein aggregates stimulate macropinocytosis in neurons to facilitate their propagation |
| Q64100713 | Searching for Bacteria in Neural Tissue From Amyotrophic Lateral Sclerosis |
| Q48148035 | Selective Motor Neuron Resistance and Recovery in a New Inducible Mouse Model of TDP-43 Proteinopathy. |
| Q39468775 | Selective mitochondrial Ca2+ uptake deficit in disease endstage vulnerable motoneurons of the SOD1G93A mouse model of amyotrophic lateral sclerosis |
| Q26996441 | Self-propagation of pathogenic protein aggregates in neurodegenerative diseases |
| Q48331848 | Semiautomated Evaluation of the Primary Motor Cortex in Patients with Amyotrophic Lateral Sclerosis at 3T. |
| Q41885438 | Sensory and motor neuronopathy in a patient with the A382P TDP-43 mutation |
| Q37678074 | Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). |
| Q58784650 | Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders |
| Q45911042 | Sexual dimorphism in ALS: exploring gender-specific neuroimaging signatures. |
| Q41634741 | Spinal cord homogenates from SOD1 familial amyotrophic lateral sclerosis induce SOD1 aggregation in living cells. |
| Q37983648 | Spinal cord markers in ALS: diagnostic and biomarker considerations |
| Q45923964 | Spinal inhibitory interneuron pathology follows motor neuron degeneration independent of glial mutant superoxide dismutase 1 expression in SOD1-ALS mice. |
| Q33552181 | Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology |
| Q37202139 | Stages of pTDP-43 pathology in amyotrophic lateral sclerosis |
| Q26995278 | Stem cell transplantation for motor neuron disease: current approaches and future perspectives |
| Q56775496 | Stem cell transplantation in amyotrophic lateral sclerosis patients: methodological approach, safety, and feasibility |
| Q61444288 | Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach |
| Q36804082 | Stress granules as crucibles of ALS pathogenesis. |
| Q38835008 | Stress granules at the intersection of autophagy and ALS. |
| Q37915428 | Stress signaling from the endoplasmic reticulum: A central player in the pathogenesis of amyotrophic lateral sclerosis. |
| Q35377964 | Structural and kinetic analysis of protein-aggregate strains in vivo using binary epitope mapping |
| Q44963319 | Structural brain network imaging shows expanding disconnection of the motor system in amyotrophic lateral sclerosis |
| Q33701772 | Structural explanation of poor prognosis of amyotrophic lateral sclerosis in the non-demented state |
| Q35830385 | Subcellular Localization of Matrin 3 Containing Mutations Associated with ALS and Distal Myopathy |
| Q59616770 | Symmetry of phrenic nerve motor response in amyotrophic lateral sclerosis |
| Q54125538 | Synaptic Paths to Neurodegeneration: The Emerging Role of TDP-43 and FUS in Synaptic Functions. |
| Q38407804 | TDP-43 in amyotrophic lateral sclerosis - is it a prion disease? |
| Q36310560 | TDP-43 is intercellularly transmitted across axon terminals |
| Q36633172 | TDP-43 or FUS-induced misfolded human wild-type SOD1 can propagate intercellularly in a prion-like fashion |
| Q35260685 | TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord |
| Q64054884 | The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD |
| Q91419222 | The biophysics of superoxide dismutase-1 and amyotrophic lateral sclerosis |
| Q38086771 | The changing scene of amyotrophic lateral sclerosis |
| Q28263899 | The complex molecular biology of amyotrophic lateral sclerosis (ALS) |
| Q39012146 | The concept and diagnostic criteria of primary lateral sclerosis |
| Q64089818 | The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? |
| Q38341406 | The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey |
| Q56929697 | The onset of ALS? |
| Q38259758 | The phenotypic variability of amyotrophic lateral sclerosis |
| Q37723166 | The present and the future of neuroimaging in amyotrophic lateral sclerosis |
| Q38102695 | The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. |
| Q51322559 | The relationship between limb dominance, disease lateralization and spread of weakness in amyotrophic lateral sclerosis (ALS). |
| Q37774045 | The role of RNA processing in the pathogenesis of motor neuron degeneration. |
| Q100533889 | The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies |
| Q58125306 | The selective anatomical vulnerability of ALS: ‘disease-defining’ and ‘disease-defying’ brain regions |
| Q34263380 | The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. |
| Q28067928 | The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review |
| Q53497564 | Time to generalisation as a predictor of prognosis in amyotrophic lateral sclerosis. |
| Q58005566 | Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study |
| Q101403304 | Topographical layer imaging as a tool to track neurodegenerative disease spread in M1 |
| Q49823859 | Towards a TDP-43-Based Biomarker for ALS and FTLD. |
| Q64075393 | Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS |
| Q47680014 | Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort |
| Q33569332 | Transfer of pathogenic and nonpathogenic cytosolic proteins between spinal cord motor neurons in vivo in chimeric mice |
| Q58271720 | Uncovering amyotrophic lateral sclerosis phenotypes: Clinical features and long-term follow-up of upper motor neuron-dominant ALS |
| Q46092568 | Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study |
| Q36733981 | Use of biomarkers in ALS drug development and clinical trials |
| Q60054023 | Utility of threshold tracking transcranial magnetic stimulation in ALS |
| Q30234813 | What causes amyotrophic lateral sclerosis? |
| Q27007017 | What does imaging reveal about the pathology of amyotrophic lateral sclerosis? |
| Q35206952 | White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis |
| Q34044019 | Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis |
Search more.